• János Galambos
  • Attila Bielik
  • Zoltán Orgován
  • György Domány
  • Katalin Nógrádi
  • Gábor Wágner
  • György T. Balogh
  • Zoltán Béni
  • János Kóti
  • Zoltán Szakács
  • Amrita Bobok
  • Sándor Kolok
  • Mónika L. Mikó-Bakk
  • Mónika Vastag
  • Katalin Sághy
  • Judit Laszy
  • Attila Sándor Halász
  • Ottilia Balázs
  • Krisztina Gál
  • István Greiner
  • Zsolt Szombathelyi
  • György M. Keserű

Negative allosteric modulators (NAM) of metabotropic glutamate receptor 5 (mGluR5) have been implicated as a potential pharmacotherapy for a number of psychiatric diseases, including anxiety and depression. Most of the mGluR5 NAM clinical candidates can be characterized by the central acetylenic moiety that connects the terminal pharmacophores. Identification of a sulfoquinoline hit via high throughput screening (HTS) followed by optimization provided a 4-phenyl-3-aryl-sulfoquinoline lead compound with the minimal pharmacophore. Optimization of the core and aryl appendages was performed by scanning and matrix libraries synthesized by the multiple parallel synthesis approach. Biological evaluation of matrix libraries provided a number of potent, metabolically stable, and in vivo active compounds. One of these compounds, 25 showed high efficacy and safety in preclinical in vivo models; this allowed its nomination as a novel, nonacetylenic mGluR5 NAM clinical candidate. Compound 25 was advanced to first-in-man trials for the treatment of psychiatric conditions.

Original languageEnglish
Pages (from-to)2470-2484
Number of pages15
JournalJournal of Medicinal Chemistry
Volume60
Issue number6
DOIs
StatePublished - 23 Mar 2017

    Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

ID: 34636238